Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer
December 20, 2021
Myriad Genetics, Inc. announced the promotion of Nicole Lambert to chief operating officer (COO). In her new role, she will continue to report directly to Paul J. Diaz, president and CEO, Myriad Genetics.
Over a 20-year career at the company, Lambert served in several senior leadership positions, most recently overseeing Myriad’s Oncology, Women’s Health and International business units as well as genetic testing laboratory operations. As COO, she assumes additional responsibility for accelerating the company’s transformation and growth plans, elevating products to their full potential, and implementing operational efficiencies to better serve patients and healthcare providers.
“Nicole is a proven leader with a deep understanding of our business and a passion for our mission of providing genetic insights that improve health and well-being for every individual,” said Diaz. “She has a unique combination of business, healthcare and operational experience coupled with strong leadership qualities and expertise in applying the power of genetics to improve patient outcomes. Nicole has been instrumental in executing our transformation to date and will now play an even broader role in accelerating our progress.”
“Over the past 20 years, I have had the honor of being a part of this incredibly committed team. I am proud of the level of excellence that Myriad provides; from accuracy in the laboratory to care and compassion in our customer service and medical teams,” said Lambert. “I have seen this impact my own family, and carry that passion into my new role, as we transform our company with an intensified focus on operational excellence, innovative science, and access for all.”
Prior to her career at Myriad, Lambert served as a genetic counselor at LabCorp. She received her bachelor’s degree in Biology and Sociology from Boston College and earned her master’s in genetic counseling from Mt. Sinai School of Medicine at New York University. She currently serves as a board member of Arcus Biosciences (NYSE: RCUS).
View the original press release here »
Media Contact:
Megan Manzari
(385) 318-3718
Megan.Manzari@myriad.com